Interindividual Variability in Hepatic Organic Anion-Transporting Polypeptides and P-Glycoprotein (ABCB1) Protein Expression: Quantification by Liquid Chromatography Tandem Mass Spectroscopy and Influence of Genotype, Age, and Sex

Interindividual variability in protein expression of organic anion-transporting polypeptides (OATPs) OATP1B1, OATP1B3, OATP2B1, and multidrug resistance-linked P-glycoprotein (P-gp) or ABCB1 was quantified in frozen human livers (n = 64) and cryopreserved human hepatocytes (n = 12) by a validated li...

Full description

Saved in:
Bibliographic Details
Published inDrug metabolism and disposition Vol. 42; no. 1; pp. 78 - 88
Main Authors Prasad, Bhagwat, Evers, Raymond, Gupta, Anshul, Hop, Cornelis E. C. A, Salphati, Laurent, Shukla, Suneet, Ambudkar, Suresh V, Unadkat, Jashvant D
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Inc 01.01.2014
The American Society for Pharmacology and Experimental Therapeutics
Subjects
Online AccessGet full text
ISSN0090-9556
1521-009X
1521-009X
DOI10.1124/dmd.113.053819

Cover

Loading…
Abstract Interindividual variability in protein expression of organic anion-transporting polypeptides (OATPs) OATP1B1, OATP1B3, OATP2B1, and multidrug resistance-linked P-glycoprotein (P-gp) or ABCB1 was quantified in frozen human livers (n = 64) and cryopreserved human hepatocytes (n = 12) by a validated liquid chromatography tandem mass spectroscopy (LC-MS/MS) method. Membrane isolation, sample workup, and LC-MS/MS analyses were as described before by our laboratory. Briefly, total native membrane proteins, isolated from the liver tissue and cryopreserved hepatocytes, were trypsin digested and quantified by LC-MS/MS using signature peptide(s) unique to each transporter. The mean ± S.D. (maximum/minimum range in parentheses) protein expression (fmol/µg of membrane protein) in human liver tissue was OATP1B1- 2.0 ± 0.9 (7), OATP1B3- 1.1 ± 0.5 (8), OATP2B1- 1 1.7 ± 0.6 (5), and P-gp- 0.4 ± 0.2 (8). Transporter expression in the liver tissue was comparable to that in the cryopreserved hepatocytes. Most important is that livers with SLCO1B1 (encoding OATP1B1) haplotypes *14/*14 and *14/*1a [i.e., representing single nucleotide polymorphisms (SNPs), c.388A > G, and c.463C > A] had significantly higher (P < 0.0001) protein expression than the reference haplotype (*1a/*1a). Based on these genotype-dependent protein expression data, we predicted (using Simcyp) an up to ∼40% decrease in the mean area under the curve of rosuvastatin or repaglinide in subjects harboring these variant alleles compared with those harboring the reference alleles. SLCO1B3 (encoding OATP1B3) SNPs did not significantly affect protein expression. Age and sex were not associated with transporter protein expression. These data will facilitate the prediction of population-based human transporter-mediated drug disposition, drug-drug interactions, and interindividual variability through physiologically based pharmacokinetic modeling.
AbstractList Interindividual variability in protein expression of organic anion-transporting polypeptides (OATPs) OATP1B1, OATP1B3, OATP2B1, and multidrug resistance-linked P-glycoprotein (P-gp) or ABCB1 was quantified in frozen human livers (n = 64) and cryopreserved human hepatocytes (n = 12) by a validated liquid chromatography tandem mass spectroscopy (LC-MS/MS) method. Membrane isolation, sample workup, and LC-MS/MS analyses were as described before by our laboratory. Briefly, total native membrane proteins, isolated from the liver tissue and cryopreserved hepatocytes, were trypsin digested and quantified by LC-MS/MS using signature peptide(s) unique to each transporter. The mean ± S.D. (maximum/minimum range in parentheses) protein expression (fmol/µg of membrane protein) in human liver tissue was OATP1B1- 2.0 ± 0.9 (7), OATP1B3- 1.1 ± 0.5 (8), OATP2B1- 1 1.7 ± 0.6 (5), and P-gp- 0.4 ± 0.2 (8). Transporter expression in the liver tissue was comparable to that in the cryopreserved hepatocytes. Most important is that livers with SLCO1B1 (encoding OATP1B1) haplotypes *14/*14 and *14/*1a [i.e., representing single nucleotide polymorphisms (SNPs), c.388A > G, and c.463C > A] had significantly higher (P < 0.0001) protein expression than the reference haplotype (*1a/*1a). Based on these genotype-dependent protein expression data, we predicted (using Simcyp) an up to ∼40% decrease in the mean area under the curve of rosuvastatin or repaglinide in subjects harboring these variant alleles compared with those harboring the reference alleles. SLCO1B3 (encoding OATP1B3) SNPs did not significantly affect protein expression. Age and sex were not associated with transporter protein expression. These data will facilitate the prediction of population-based human transporter-mediated drug disposition, drug-drug interactions, and interindividual variability through physiologically based pharmacokinetic modeling.
Interindividual variability in protein expression of organic anion-transporting polypeptides (OATPs) OATP1B1, OATP1B3, OATP2B1, and multidrug resistance-linked P-glycoprotein (P-gp) or ABCB1 was quantified in frozen human livers ( n = 64) and cryopreserved human hepatocytes ( n = 12) by a validated liquid chromatography tandem mass spectroscopy (LC-MS/MS) method. Membrane isolation, sample workup, and LC-MS/MS analyses were as described before by our laboratory. Briefly, total native membrane proteins, isolated from the liver tissue and cryopreserved hepatocytes, were trypsin digested and quantified by LC-MS/MS using signature peptide(s) unique to each transporter. The mean ± S.D. (maximum/minimum range in parentheses) protein expression (fmol/ µ g of membrane protein) in human liver tissue was OATP1B1- 2.0 ± 0.9 (7), OATP1B3- 1.1 ± 0.5 (8), OATP2B1- 1 1.7 ± 0.6 (5), and P-gp- 0.4 ± 0.2 (8). Transporter expression in the liver tissue was comparable to that in the cryopreserved hepatocytes. Most important is that livers with SLCO1B1 (encoding OATP1B1) haplotypes *14/*14 and *14/*1a [i.e., representing single nucleotide polymorphisms (SNPs), c.388A > G, and c.463C > A] had significantly higher ( P < 0.0001) protein expression than the reference haplotype (*1a/*1a). Based on these genotype-dependent protein expression data, we predicted (using Simcyp) an up to ∼40% decrease in the mean area under the curve of rosuvastatin or repaglinide in subjects harboring these variant alleles compared with those harboring the reference alleles. SLCO1B3 (encoding OATP1B3) SNPs did not significantly affect protein expression. Age and sex were not associated with transporter protein expression. These data will facilitate the prediction of population-based human transporter-mediated drug disposition, drug-drug interactions, and interindividual variability through physiologically based pharmacokinetic modeling.
Interindividual variability in protein expression of organic anion-transporting polypeptides (OATPs) OATP1B1, OATP1B3, OATP2B1, and multidrug resistance-linked P-glycoprotein (P-gp) or ABCB1 was quantified in frozen human livers (n = 64) and cryopreserved human hepatocytes (n = 12) by a validated liquid chromatography tandem mass spectroscopy (LC-MS/MS) method. Membrane isolation, sample workup, and LC-MS/MS analyses were as described before by our laboratory. Briefly, total native membrane proteins, isolated from the liver tissue and cryopreserved hepatocytes, were trypsin digested and quantified by LC-MS/MS using signature peptide(s) unique to each transporter. The mean ± S.D. (maximum/minimum range in parentheses) protein expression (fmol/µg of membrane protein) in human liver tissue was OATP1B1- 2.0 ± 0.9 (7), OATP1B3- 1.1 ± 0.5 (8), OATP2B1- 1 1.7 ± 0.6 (5), and P-gp- 0.4 ± 0.2 (8). Transporter expression in the liver tissue was comparable to that in the cryopreserved hepatocytes. Most important is that livers with SLCO1B1 (encoding OATP1B1) haplotypes *14/*14 and *14/*1a [i.e., representing single nucleotide polymorphisms (SNPs), c.388A > G, and c.463C > A] had significantly higher (P < 0.0001) protein expression than the reference haplotype (*1a/*1a). Based on these genotype-dependent protein expression data, we predicted (using Simcyp) an up to ∼40% decrease in the mean area under the curve of rosuvastatin or repaglinide in subjects harboring these variant alleles compared with those harboring the reference alleles. SLCO1B3 (encoding OATP1B3) SNPs did not significantly affect protein expression. Age and sex were not associated with transporter protein expression. These data will facilitate the prediction of population-based human transporter-mediated drug disposition, drug-drug interactions, and interindividual variability through physiologically based pharmacokinetic modeling.Interindividual variability in protein expression of organic anion-transporting polypeptides (OATPs) OATP1B1, OATP1B3, OATP2B1, and multidrug resistance-linked P-glycoprotein (P-gp) or ABCB1 was quantified in frozen human livers (n = 64) and cryopreserved human hepatocytes (n = 12) by a validated liquid chromatography tandem mass spectroscopy (LC-MS/MS) method. Membrane isolation, sample workup, and LC-MS/MS analyses were as described before by our laboratory. Briefly, total native membrane proteins, isolated from the liver tissue and cryopreserved hepatocytes, were trypsin digested and quantified by LC-MS/MS using signature peptide(s) unique to each transporter. The mean ± S.D. (maximum/minimum range in parentheses) protein expression (fmol/µg of membrane protein) in human liver tissue was OATP1B1- 2.0 ± 0.9 (7), OATP1B3- 1.1 ± 0.5 (8), OATP2B1- 1 1.7 ± 0.6 (5), and P-gp- 0.4 ± 0.2 (8). Transporter expression in the liver tissue was comparable to that in the cryopreserved hepatocytes. Most important is that livers with SLCO1B1 (encoding OATP1B1) haplotypes *14/*14 and *14/*1a [i.e., representing single nucleotide polymorphisms (SNPs), c.388A > G, and c.463C > A] had significantly higher (P < 0.0001) protein expression than the reference haplotype (*1a/*1a). Based on these genotype-dependent protein expression data, we predicted (using Simcyp) an up to ∼40% decrease in the mean area under the curve of rosuvastatin or repaglinide in subjects harboring these variant alleles compared with those harboring the reference alleles. SLCO1B3 (encoding OATP1B3) SNPs did not significantly affect protein expression. Age and sex were not associated with transporter protein expression. These data will facilitate the prediction of population-based human transporter-mediated drug disposition, drug-drug interactions, and interindividual variability through physiologically based pharmacokinetic modeling.
Author Prasad, Bhagwat
Unadkat, Jashvant D
Ambudkar, Suresh V
Hop, Cornelis E. C. A
Gupta, Anshul
Shukla, Suneet
Evers, Raymond
Salphati, Laurent
Author_xml – sequence: 1
  givenname: Bhagwat
  surname: Prasad
  fullname: Prasad, Bhagwat
– sequence: 2
  givenname: Raymond
  surname: Evers
  fullname: Evers, Raymond
– sequence: 3
  givenname: Anshul
  surname: Gupta
  fullname: Gupta, Anshul
– sequence: 4
  givenname: Cornelis E. C. A
  surname: Hop
  fullname: Hop, Cornelis E. C. A
– sequence: 5
  givenname: Laurent
  surname: Salphati
  fullname: Salphati, Laurent
– sequence: 6
  givenname: Suneet
  surname: Shukla
  fullname: Shukla, Suneet
– sequence: 7
  givenname: Suresh V
  surname: Ambudkar
  fullname: Ambudkar, Suresh V
– sequence: 8
  givenname: Jashvant D
  surname: Unadkat
  fullname: Unadkat, Jashvant D
  email: jash@u.washington.edu
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24122874$$D View this record in MEDLINE/PubMed
BookMark eNp1Uk1vEzEQXaEimhauHJGPRWLDer-y5lApjUoaKahBDYib5fXOJoN27a3tjbp_mN-B06QIkHrxG2vmvTeambPgRGkFQfCWRmNK4_Rj1VY-SMZRlhSUvQhGNItpGEXsx0kw8hCFLMvy0-DM2p9RRNM0Ya-C0zilcVxM0lHwa6EcGFQV7rDqRUO-C4OixAbdQFCRG-iEQ0luzUYoj1OFWoVrI5TttHGoNmSlm6GDzmEFlghVkVU4bwapO6MdeImL6dXsir4nq-P_-qEzYK3X-US-9kI5rFF6E61IOZAl3vdYkdnW6FY4vTGi2w5k7XWhJV-EteSuA-mMtt5hePRbqLrpQUkguiZzUNr5fj6Q6cY_-_wdPLwOXtaisfDmiOfBt8_X69lNuLydL2bTZSizKHMhyLRkVZ6UccFAClZVEvIkZ2lWpBnLClonULBCiDjLs6JmSTmp8yJnkKc0yWSSnAeXB92uL1vwbOWMaHhnsBVm4Fog_zejcMs3eseTYpJPWOQFLo4CRt_3YB1v0UpoGqFA95bTNGcx3ffjS9_97fXH5Gm5viA9FEg_LWug5hLd46C9NTacRnx_Q9zfkA8SfrghTxv_R3tSfpZQHAjgJ7tDMNxK3O-jQuNXxSuNz1F_AzQP4WQ
CitedBy_id crossref_primary_10_1016_j_jpba_2018_11_013
crossref_primary_10_1124_dmd_114_058446
crossref_primary_10_1146_annurev_anchem_091719_024553
crossref_primary_10_3389_fphys_2017_00123
crossref_primary_10_1124_dmd_114_061614
crossref_primary_10_1158_1078_0432_CCR_16_2245
crossref_primary_10_1111_cts_13444
crossref_primary_10_1002_psp4_12168
crossref_primary_10_1124_dmd_115_063362
crossref_primary_10_1002_hep4_1489
crossref_primary_10_1124_dmd_114_061580
crossref_primary_10_1124_dmd_120_000122
crossref_primary_10_3389_fphar_2015_00013
crossref_primary_10_1002_psp4_12170
crossref_primary_10_1124_dmd_115_064170
crossref_primary_10_1002_cpt_819
crossref_primary_10_1124_jpet_119_263459
crossref_primary_10_1039_D3MO00144J
crossref_primary_10_1124_dmd_118_084988
crossref_primary_10_1038_s41598_019_45778_9
crossref_primary_10_1021_acs_molpharmaceut_8b01189
crossref_primary_10_1002_prp2_1082
crossref_primary_10_1124_dmd_114_062034
crossref_primary_10_1016_j_ejps_2018_08_042
crossref_primary_10_1007_s11095_019_2634_3
crossref_primary_10_3390_ijms17091502
crossref_primary_10_1124_dmd_117_076703
crossref_primary_10_1124_pharmrev_121_000449
crossref_primary_10_1016_j_ab_2016_06_006
crossref_primary_10_1096_fasebj_31_1_supplement_669_13
crossref_primary_10_1208_s12248_014_9602_y
crossref_primary_10_3390_pharmaceutics14050915
crossref_primary_10_1002_jcph_671
crossref_primary_10_1128_AAC_00955_20
crossref_primary_10_1016_j_ddtec_2021_06_002
crossref_primary_10_1124_dmd_121_000805
crossref_primary_10_1016_j_ddtec_2021_06_008
crossref_primary_10_1124_dmd_113_056309
crossref_primary_10_1016_j_bcp_2021_114534
crossref_primary_10_1021_acs_molpharmaceut_8b00941
crossref_primary_10_1038_s41420_021_00621_x
crossref_primary_10_1124_dmd_114_056929
crossref_primary_10_1039_D4AN01514B
crossref_primary_10_1007_s11095_014_1446_8
crossref_primary_10_1002_prca_201400147
crossref_primary_10_1124_dmd_114_057976
crossref_primary_10_1016_j_xphs_2017_03_027
crossref_primary_10_3390_pharmaceutics9010008
crossref_primary_10_1002_cpt_409
crossref_primary_10_1002_jcph_703
crossref_primary_10_29413_ABS_2021_6_6_2_12
crossref_primary_10_1124_dmd_114_059873
crossref_primary_10_1016_j_jchromb_2019_01_005
crossref_primary_10_1007_s11095_016_1966_5
crossref_primary_10_1208_s12248_019_0359_1
crossref_primary_10_1007_s40268_019_00285_0
crossref_primary_10_1016_j_xphs_2017_03_023
crossref_primary_10_3389_fnbeh_2022_844916
crossref_primary_10_1002_cpt_1373
crossref_primary_10_1124_dmd_119_089656
crossref_primary_10_1016_j_pharmr_2024_100023
crossref_primary_10_1124_dmd_119_086785
crossref_primary_10_1002_jcph_1489
crossref_primary_10_1093_toxsci_kfw236
crossref_primary_10_3109_03602532_2014_882353
crossref_primary_10_1016_j_ejps_2020_105395
crossref_primary_10_1002_cpt_1537
crossref_primary_10_1016_j_pharmthera_2019_107397
crossref_primary_10_1007_s11095_022_03387_8
crossref_primary_10_1016_j_jpba_2015_02_043
crossref_primary_10_3390_biomedicines11061633
crossref_primary_10_1124_dmd_121_000476
crossref_primary_10_1124_dmd_116_072066
crossref_primary_10_1080_17460441_2018_1493454
crossref_primary_10_3389_fphar_2021_715577
crossref_primary_10_1038_s41598_019_46977_0
crossref_primary_10_1124_dmd_115_067538
crossref_primary_10_1016_j_apsb_2025_03_030
crossref_primary_10_1096_fasebj_31_1_supplement_668_17
crossref_primary_10_1124_dmd_115_067371
crossref_primary_10_1124_dmd_118_080952
crossref_primary_10_1016_j_bcp_2014_09_025
crossref_primary_10_1016_j_ejps_2020_105264
crossref_primary_10_1124_dmd_116_071183
crossref_primary_10_1002_cpt_2556
crossref_primary_10_1080_17425255_2018_1546288
crossref_primary_10_3390_molecules25112718
crossref_primary_10_1016_j_ijpharm_2016_04_024
crossref_primary_10_1124_dmd_116_074732
crossref_primary_10_1124_dmd_117_077289
crossref_primary_10_1124_dmd_116_074575
crossref_primary_10_1038_psp_2014_24
crossref_primary_10_3109_03602532_2014_921190
crossref_primary_10_1124_dmd_115_067801
crossref_primary_10_1124_dmd_115_068577
crossref_primary_10_3109_00498254_2015_1085111
crossref_primary_10_1155_2014_451510
crossref_primary_10_1002_jps_24336
crossref_primary_10_1016_j_ejps_2022_106246
crossref_primary_10_1124_dmd_117_076745
crossref_primary_10_1124_jpet_117_243113
crossref_primary_10_1007_s11883_017_0701_y
crossref_primary_10_1021_acs_molpharmaceut_1c00083
crossref_primary_10_1097_HC9_0000000000000031
crossref_primary_10_1002_cpt_176
crossref_primary_10_1124_dmd_121_000451
crossref_primary_10_1080_03602532_2021_1922435
crossref_primary_10_1124_dmd_117_076463
crossref_primary_10_1208_s12248_014_9607_6
crossref_primary_10_1080_10408347_2021_1891859
crossref_primary_10_2217_pgs_15_18
crossref_primary_10_1124_dmd_115_069252
crossref_primary_10_18632_oncotarget_13135
crossref_primary_10_1093_toxsci_kfv110
crossref_primary_10_1517_17425255_2015_1055245
crossref_primary_10_1016_j_dmpk_2015_06_005
crossref_primary_10_1007_s11095_021_03107_8
crossref_primary_10_1124_dmd_116_072652
crossref_primary_10_3109_03602532_2016_1157600
crossref_primary_10_1208_s12248_016_0009_9
crossref_primary_10_1124_pharmrev_120_000071
crossref_primary_10_1002_jcph_740
crossref_primary_10_1080_17425255_2025_2481891
crossref_primary_10_1080_17425255_2020_1749595
crossref_primary_10_3389_fphys_2021_757293
crossref_primary_10_1124_dmd_118_080523
crossref_primary_10_1016_j_apsb_2022_03_009
crossref_primary_10_1002_cpt_3354
crossref_primary_10_1038_tpj_2015_58
crossref_primary_10_1016_j_phrs_2017_01_018
crossref_primary_10_1016_j_ejps_2019_01_022
crossref_primary_10_1159_000362822
crossref_primary_10_1007_s40262_014_0156_z
crossref_primary_10_1111_bcp_14230
crossref_primary_10_1124_dmd_116_071050
crossref_primary_10_1038_s41401_021_00692_7
crossref_primary_10_3390_pharmaceutics14081734
crossref_primary_10_1016_j_pharep_2019_04_001
crossref_primary_10_1016_j_jchromb_2017_07_051
crossref_primary_10_1007_s40262_015_0267_1
crossref_primary_10_1007_s40262_015_0328_5
crossref_primary_10_1002_cyto_b_21729
crossref_primary_10_1002_jcph_695
crossref_primary_10_1124_dmd_120_000134
crossref_primary_10_1016_j_jchromb_2018_03_007
crossref_primary_10_1002_mnfr_201400095
crossref_primary_10_1002_jcph_1604
crossref_primary_10_1007_s13318_022_00802_8
crossref_primary_10_1016_j_xphs_2016_11_017
crossref_primary_10_1096_fasebj_30_1_supplement_713_11
crossref_primary_10_1021_acs_molpharmaceut_8b00320
Cites_doi 10.1002/rcm.5026
10.1038/clpt.2010.255
10.1111/j.1365-2125.2008.03287.x
10.1097/FPC.0b013e32830d733e
10.1515/cclm.2011.804
10.3851/IMP2095
10.1021/jm300212s
10.1002/hep.21214
10.1124/dmd.111.043489
10.1074/jbc.M103792200
10.1016/j.bcp.2011.10.017
10.1016/j.aca.2011.12.005
10.1615/CritRevBiomedEng.v40.i4.50
10.1161/CIRCGENETICS.109.898502
10.1097/01.fpc.0000170913.73780.5f
10.1097/01.fpc.0000114750.08559.32
10.1038/clpt.2009.232
10.1007/s11095-012-0956-5
10.1074/jbc.M601917200
10.1016/j.clpt.2003.12.014
10.1124/jpet.104.068536
10.1067/mcp.2002.128469
10.1002/jps.23436
10.3390/ijms12095815
10.1016/S0014-2565(01)70966-6
10.1124/dmd.111.043810
10.1517/17425255.2013.741589
10.1016/S0002-9343(00)00514-3
10.1097/FPC.0b013e328335b02d
10.1016/j.clpt.2003.12.016
10.1007/s11095-008-9532-4
10.1056/NEJMoa0801936
10.1186/gm405
10.1002/bdd.1810
10.1016/j.ejps.2005.12.003
10.1016/j.jacc.2009.04.053
10.1007/s11095-012-0792-7
10.1124/dmd.111.042275
10.1021/mp300379q
10.1038/nrd3028
10.1124/dmd.111.042259
10.1016/S0022-3565(24)37149-6
ContentType Journal Article
Copyright 2013 American Society for Pharmacology and Experimental Therapeutics
U.S. Government work not protected by U.S. copyright 2014
Copyright_xml – notice: 2013 American Society for Pharmacology and Experimental Therapeutics
– notice: U.S. Government work not protected by U.S. copyright 2014
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1124/dmd.113.053819
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Interindividual Variability in Hepatic Transporter Expression
EISSN 1521-009X
EndPage 88
ExternalDocumentID PMC3876790
24122874
10_1124_dmd_113_053819
S0090955624098118
Genre Research Support, U.S. Gov't, P.H.S
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Intramural NIH HHS
  grantid: ZIA BC010030
– fundername: NCI NIH HHS
  grantid: ZIA BC010030-13
GroupedDBID ---
.GJ
0R~
18M
2WC
4.4
53G
5GY
5RE
5VS
AAXUO
ABJNI
ABSQV
ACGFO
ACGFS
ACIWK
ACPRK
ADBBV
AENEX
AERNN
AFFNX
AFOSN
AFRAH
AI.
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
F9R
FDB
GX1
H13
HZ~
IH2
INIJC
KQ8
LSO
M41
O9-
OK1
P2P
R0Z
RHI
ROL
RPT
SJN
TR2
VH1
W8F
WH7
WOQ
YCJ
YHG
ZGI
ZXP
~KM
AALRI
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c505t-ec4b9d63b289eca9ddce6369458459581f3e898aa25658f93b7f6869e64135c33
ISSN 0090-9556
1521-009X
IngestDate Thu Aug 21 14:33:09 EDT 2025
Fri Jul 11 14:16:40 EDT 2025
Mon Jul 21 05:54:39 EDT 2025
Thu Apr 24 23:08:39 EDT 2025
Tue Jul 01 05:28:21 EDT 2025
Sun Apr 06 06:53:01 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords BCRP
BCA
P-gp
DDI
PBPK
CL
MRM
OATP
AUC
LC-MS/MS
MRP-2
SNP
SIL
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c505t-ec4b9d63b289eca9ddce6369458459581f3e898aa25658f93b7f6869e64135c33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
R.E., A.G., C.E.H., and L.S. contributed equally to the research.
OpenAccessLink https://dmd.aspetjournals.org/content/dmd/42/1/78.full.pdf
PMID 24122874
PQID 1469214584
PQPubID 23479
PageCount 11
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_3876790
proquest_miscellaneous_1469214584
pubmed_primary_24122874
crossref_citationtrail_10_1124_dmd_113_053819
crossref_primary_10_1124_dmd_113_053819
elsevier_sciencedirect_doi_10_1124_dmd_113_053819
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate January 2014
2014-01-00
2014-Jan
20140101
PublicationDateYYYYMMDD 2014-01-01
PublicationDate_xml – month: 01
  year: 2014
  text: January 2014
PublicationDecade 2010
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
– name: Bethesda, MD
PublicationTitle Drug metabolism and disposition
PublicationTitleAlternate Drug Metab Dispos
PublicationYear 2014
Publisher Elsevier Inc
The American Society for Pharmacology and Experimental Therapeutics
Publisher_xml – name: Elsevier Inc
– name: The American Society for Pharmacology and Experimental Therapeutics
References Marsà Carretero, Alos Manrique, Valles Callol (bib24) 2002; 52
Alexandridis, Pappas, Elisaf (bib2) 2000; 109
Link, Parish, Armitage, Bowman, Heath, Matsuda, Gut, Lathrop, Collins (bib22) 2008; 359
Rodrigues, Perin, Purim, Silbiger, Genvigir, Willrich, Arazi, Luchessi, Hirata, Bernik (bib34) 2011; 12
Varma, Lai, Feng, Litchfield, Goosen, Bergman (bib45) 2012; 29
Kameyama, Yamashita, Kobayashi, Hosokawa, Chiba (bib18) 2005; 15
Ohtsuki, Schaefer, Kawakami, Inoue, Liehner, Saito, Ishiguro, Kishimoto, Ludwig-Schwellinger, Ebner (bib30) 2012; 40
Zhang, Li, Brown, Ozer, Lai (bib48) 2011; 25
Sortica, Fiegenbaum, Lima, Van der Sand, Van der Sand, Ferreira, Pires, Hutz (bib41) 2012; 50
Shitara, Hirano, Sato, Sugiyama (bib39) 2004; 311
Karlgren, Vildhede, Norinder, Wisniewski, Kimoto, Lai, Haglund, Artursson (bib20) 2012; 55
Giacomini, Huang, Tweedie, Benet, Brouwer, Chu, Dahlin, Evers, Fischer, Hillgren (bib11) 2010; 9
Bailey, Romaine, Jackson, Farrin, Efthymiou, Barth, Copeland, McCormack, Whitehead, Flather (bib4) 2010; 3
Kalliokoski, Neuvonen, Neuvonen, Niemi (bib17) 2008; 66
Meier, Pauli-Magnus, Zanger, Klein, Schaeffeler, Nussler, Nussler, Eichelbaum, Meier, Stieger (bib26) 2006; 44
Mwinyi, Johne, Bauer, Roots, Gerloff (bib27) 2004; 75
Harwood, Neuhoff, Carlson, Warhurst, Rostami-Hodjegan (bib13) 2013; 34
Sauna, Nandigama, Ambudkar (bib35) 2006; 281
Prasad, Lai, Lin, Unadkat (bib33) 2013; 102
Tomlinson, Hu, Lee, Lui, Chu, Poon, Ko, Baum, Tam, Li (bib43) 2010; 87
Varma, Lai, Kimoto, Goosen, El-Kattan, Kumar (bib46) 2013; 30
Kimoto, Yoshida, Balogh, Bi, Maeda, El-Kattan, Sugiyama, Lai (bib21) 2012; 9
Schneck, Birmingham, Zalikowski, Mitchell, Wang, Martin, Lasseter, Brown, Windass, Raza (bib38) 2004; 75
Deo, Prasad, Balogh, Lai, Unadkat (bib9) 2012; 40
Hartkoorn, Kwan, Shallcross, Chaikan, Liptrott, Egan, Sora, James, Gibbons, Bray (bib12) 2010; 20
Tucker, Milne, Fournel-Gigleux, Fenner, Coughtrie (bib44) 2012; 83
Donnelly, Doney, Tavendale, Lang, Pearson, Colhoun, McCarthy, Hattersley, Morris, Palmer (bib10) 2011; 89
Schipani, Egan, Dickinson, Davies, Boffito, Youle, Khoo, Back, Owen (bib37) 2012; 17
Backman, Kyrklund, Neuvonen, Neuvonen (bib3) 2002; 72
Bi, Kimoto, Sevidal, Jones, Barton, Kempshall, Whalen, Zhang, Ji, Fenner (bib6) 2012; 40
Lon, Liu, Jusko (bib23) 2012; 40
Kamiie, Ohtsuki, Iwase, Ohmine, Katsukura, Yanai, Sekine, Uchida, Ito, Terasaki (bib19) 2008; 25
Balogh, Kimoto, Chupka, Zhang, Lai (bib5) 2012; 84
Tirona, Leake, Merino, Kim (bib42) 2001; 276
Bosch Rovira, Llompart Pou, Forteza-Rey (bib7) 2001; 201
Voora, Shah, Spasojevic, Ali, Reed, Salisbury, Ginsburg (bib47) 2009; 54
Niemi, Schaeffeler, Lang, Fromm, Neuvonen, Kyrklund, Backman, Kerb, Schwab, Neuvonen (bib28) 2004; 14
Chu, Bleasby, Evers (bib8) 2013; 9
Kalliokoski, Backman, Neuvonen, Niemi (bib16) 2008; 18
Ji, Tschantz, Pfeifer, Ullah, Sadagopan (bib14) 2012; 717
Shitara, Horie, Sugiyama (bib40) 2006; 27
Paine, Khalighi, Fisher, Shen, Kunze, Marsh, Perkins, Thummel (bib31) 1997; 283
Schaefer, Ohtsuki, Kawakami, Inoue, Liehner, Saito, Sakamoto, Ishiguro, Matsumaru, Terasaki (bib36) 2012; 40
Nies, Niemi, Burk, Winter, Zanger, Stieger, Schwab, Schaeffeler (bib29) 2013; 5
Marsà Carretero (10.1124/dmd.113.053819_bib24) 2002; 52
Shitara (10.1124/dmd.113.053819_bib39) 2004; 311
Varma (10.1124/dmd.113.053819_bib46) 2013; 30
Hartkoorn (10.1124/dmd.113.053819_bib12) 2010; 20
Sauna (10.1124/dmd.113.053819_bib35) 2006; 281
Deo (10.1124/dmd.113.053819_bib9) 2012; 40
Prasad (10.1124/dmd.113.053819_bib33) 2013; 102
Meier (10.1124/dmd.113.053819_bib26) 2006; 44
Chu (10.1124/dmd.113.053819_bib8) 2013; 9
Shitara (10.1124/dmd.113.053819_bib40) 2006; 27
Kameyama (10.1124/dmd.113.053819_bib18) 2005; 15
Kalliokoski (10.1124/dmd.113.053819_bib16) 2008; 18
Niemi (10.1124/dmd.113.053819_bib28) 2004; 14
Harwood (10.1124/dmd.113.053819_bib13) 2013; 34
Schipani (10.1124/dmd.113.053819_bib37) 2012; 17
Bailey (10.1124/dmd.113.053819_bib4) 2010; 3
Donnelly (10.1124/dmd.113.053819_bib10) 2011; 89
Lon (10.1124/dmd.113.053819_bib23) 2012; 40
Mwinyi (10.1124/dmd.113.053819_bib27) 2004; 75
Sortica (10.1124/dmd.113.053819_bib41) 2012; 50
Bosch Rovira (10.1124/dmd.113.053819_bib7) 2001; 201
Nies (10.1124/dmd.113.053819_bib29) 2013; 5
Backman (10.1124/dmd.113.053819_bib3) 2002; 72
Ohtsuki (10.1124/dmd.113.053819_bib30) 2012; 40
Rodrigues (10.1124/dmd.113.053819_bib34) 2011; 12
Zhang (10.1124/dmd.113.053819_bib48) 2011; 25
Varma (10.1124/dmd.113.053819_bib45) 2012; 29
Alexandridis (10.1124/dmd.113.053819_bib2) 2000; 109
Schaefer (10.1124/dmd.113.053819_bib36) 2012; 40
Kalliokoski (10.1124/dmd.113.053819_bib17) 2008; 66
Giacomini (10.1124/dmd.113.053819_bib11) 2010; 9
Paine (10.1124/dmd.113.053819_bib31) 1997; 283
Link (10.1124/dmd.113.053819_bib22) 2008; 359
Schneck (10.1124/dmd.113.053819_bib38) 2004; 75
Voora (10.1124/dmd.113.053819_bib47) 2009; 54
Tucker (10.1124/dmd.113.053819_bib44) 2012; 83
Kimoto (10.1124/dmd.113.053819_bib21) 2012; 9
Balogh (10.1124/dmd.113.053819_bib5) 2012; 84
Kamiie (10.1124/dmd.113.053819_bib19) 2008; 25
Ji (10.1124/dmd.113.053819_bib14) 2012; 717
Bi (10.1124/dmd.113.053819_bib6) 2012; 40
Karlgren (10.1124/dmd.113.053819_bib20) 2012; 55
Tirona (10.1124/dmd.113.053819_bib42) 2001; 276
Tomlinson (10.1124/dmd.113.053819_bib43) 2010; 87
References_xml – volume: 72
  start-page: 685
  year: 2002
  end-page: 691
  ident: bib3
  article-title: Gemfibrozil greatly increases plasma concentrations of cerivastatin
  publication-title: Clin Pharmacol Ther
– volume: 18
  start-page: 937
  year: 2008
  end-page: 942
  ident: bib16
  article-title: Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide
  publication-title: Pharmacogenet Genomics
– volume: 201
  start-page: 731
  year: 2001
  end-page: 732
  ident: bib7
  article-title: [Rhabdomyolysis associated with combined treatment of cerivastatin and gemfibrozil]
  publication-title: Rev Clin Esp
– volume: 25
  start-page: 1715
  year: 2011
  end-page: 1724
  ident: bib48
  article-title: Liquid chromatography/tandem mass spectrometry based targeted proteomics quantification of P-glycoprotein in various biological samples
  publication-title: Rapid Commun Mass Spectrom
– volume: 40
  start-page: 93
  year: 2012
  end-page: 103
  ident: bib36
  article-title: Absolute quantification and differential expression of drug transporters, cytochrome P450 enzymes, and UDP-glucuronosyltransferases in cultured primary human hepatocytes
  publication-title: Drug Metab Dispos
– volume: 83
  start-page: 279
  year: 2012
  end-page: 285
  ident: bib44
  article-title: Absolute immunoquantification of the expression of ABC transporters P-glycoprotein, breast cancer resistance protein and multidrug resistance-associated protein 2 in human liver and duodenum
  publication-title: Biochem Pharmacol
– volume: 29
  start-page: 2860
  year: 2012
  end-page: 2873
  ident: bib45
  article-title: Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions
  publication-title: Pharm Res
– volume: 9
  start-page: 237
  year: 2013
  end-page: 252
  ident: bib8
  article-title: Species differences in drug transporters and implications for translating preclinical findings to humans
  publication-title: Expert Opin Drug Metab Toxicol
– volume: 55
  start-page: 4740
  year: 2012
  end-page: 4763
  ident: bib20
  article-title: Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions
  publication-title: J Med Chem
– volume: 40
  start-page: 83
  year: 2012
  end-page: 92
  ident: bib30
  article-title: Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities
  publication-title: Drug Metab Dispos
– volume: 283
  start-page: 1552
  year: 1997
  end-page: 1562
  ident: bib31
  article-title: Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism
  publication-title: J Pharmacol Exp Ther
– volume: 9
  start-page: 3535
  year: 2012
  end-page: 3542
  ident: bib21
  article-title: Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes
  publication-title: Mol Pharm
– volume: 3
  start-page: 276
  year: 2010
  end-page: 285
  ident: bib4
  article-title: Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study
  publication-title: Circ Cardiovasc Genet
– volume: 281
  start-page: 26501
  year: 2006
  end-page: 26511
  ident: bib35
  article-title: Exploiting reaction intermediates of the ATPase reaction to elucidate the mechanism of transport by P-glycoprotein (ABCB1)
  publication-title: J Biol Chem
– volume: 75
  start-page: 455
  year: 2004
  end-page: 463
  ident: bib38
  article-title: The effect of gemfibrozil on the pharmacokinetics of rosuvastatin
  publication-title: Clin Pharmacol Ther
– volume: 75
  start-page: 415
  year: 2004
  end-page: 421
  ident: bib27
  article-title: Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics
  publication-title: Clin Pharmacol Ther
– volume: 52
  start-page: 235
  year: 2002
  end-page: 236
  ident: bib24
  article-title: Rhabdomyolysis associated with cerivastatin plus gemfibrozil combined regimen
  publication-title: Br J Gen Pract
– volume: 27
  start-page: 425
  year: 2006
  end-page: 446
  ident: bib40
  article-title: Transporters as a determinant of drug clearance and tissue distribution
  publication-title: Eur J Pharm Sci
– volume: 30
  start-page: 1188
  year: 2013
  end-page: 1199
  ident: bib46
  article-title: Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide
  publication-title: Pharm Res
– volume: 40
  start-page: 1085
  year: 2012
  end-page: 1092
  ident: bib6
  article-title: In vitro evaluation of hepatic transporter-mediated clinical drug-drug interactions: hepatocyte model optimization and retrospective investigation
  publication-title: Drug Metab Dispos
– volume: 12
  start-page: 5815
  year: 2011
  end-page: 5827
  ident: bib34
  article-title: Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response
  publication-title: Int J Mol Sci
– volume: 17
  start-page: 861
  year: 2012
  end-page: 868
  ident: bib37
  article-title: Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults
  publication-title: Antivir Ther
– volume: 34
  start-page: 2
  year: 2013
  end-page: 28
  ident: bib13
  article-title: Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption
  publication-title: Biopharm Drug Dispos
– volume: 66
  start-page: 818
  year: 2008
  end-page: 825
  ident: bib17
  article-title: The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range
  publication-title: Br J Clin Pharmacol
– volume: 15
  start-page: 513
  year: 2005
  end-page: 522
  ident: bib18
  article-title: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells
  publication-title: Pharmacogenet Genomics
– volume: 87
  start-page: 558
  year: 2010
  end-page: 562
  ident: bib43
  article-title: ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin
  publication-title: Clin Pharmacol Ther
– volume: 54
  start-page: 1609
  year: 2009
  end-page: 1616
  ident: bib47
  article-title: The SLCO1B1*5 genetic variant is associated with statin-induced side effects
  publication-title: J Am Coll Cardiol
– volume: 109
  start-page: 261
  year: 2000
  end-page: 262
  ident: bib2
  article-title: Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil
  publication-title: Am J Med
– volume: 20
  start-page: 112
  year: 2010
  end-page: 120
  ident: bib12
  article-title: HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms
  publication-title: Pharmacogenet Genomics
– volume: 40
  start-page: 295
  year: 2012
  end-page: 312
  ident: bib23
  article-title: Pharmacokinetic/pharmacodynamic modeling in inflammation
  publication-title: Crit Rev Biomed Eng
– volume: 717
  start-page: 67
  year: 2012
  end-page: 76
  ident: bib14
  article-title: Development of a multiplex UPLC-MRM MS method for quantification of human membrane transport proteins OATP1B1, OATP1B3 and OATP2B1 in in vitro systems and tissues
  publication-title: Anal Chim Acta
– volume: 276
  start-page: 35669
  year: 2001
  end-page: 35675
  ident: bib42
  article-title: Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans
  publication-title: J Biol Chem
– volume: 25
  start-page: 1469
  year: 2008
  end-page: 1483
  ident: bib19
  article-title: Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria
  publication-title: Pharm Res
– volume: 14
  start-page: 429
  year: 2004
  end-page: 440
  ident: bib28
  article-title: High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)
  publication-title: Pharmacogenetics
– volume: 311
  start-page: 228
  year: 2004
  end-page: 236
  ident: bib39
  article-title: Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil
  publication-title: J Pharmacol Exp Ther
– volume: 89
  start-page: 210
  year: 2011
  end-page: 216
  ident: bib10
  article-title: Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study
  publication-title: Clin Pharmacol Ther
– volume: 40
  start-page: 852
  year: 2012
  end-page: 855
  ident: bib9
  article-title: Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry
  publication-title: Drug Metab Dispos
– volume: 5
  start-page: 1
  year: 2013
  end-page: 11
  ident: bib29
  article-title: Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1
  publication-title: Genome Med
– volume: 50
  start-page: 441
  year: 2012
  end-page: 448
  ident: bib41
  article-title: SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians
  publication-title: Clin Chem Lab Med
– volume: 84
  start-page: 1
  year: 2012
  end-page: 8
  ident: bib5
  article-title: Membrane protein quantification by peptide-based mass spectrometry approaches: studies on the organic anion-transporting polypeptide family
  publication-title: J Proteomics Bioinform
– volume: 102
  start-page: 787
  year: 2013
  end-page: 793
  ident: bib33
  article-title: Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype
  publication-title: J Pharm Sci
– volume: 359
  start-page: 789
  year: 2008
  end-page: 799
  ident: bib22
  article-title: SLCO1B1 variants and statin-induced myopathy—a genomewide study
  publication-title: N Engl J Med
– volume: 9
  start-page: 215
  year: 2010
  end-page: 236
  ident: bib11
  article-title: Membrane transporters in drug development
  publication-title: Nat Rev Drug Discov
– volume: 44
  start-page: 62
  year: 2006
  end-page: 74
  ident: bib26
  article-title: Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver
  publication-title: Hepatology
– volume: 25
  start-page: 1715
  year: 2011
  ident: 10.1124/dmd.113.053819_bib48
  article-title: Liquid chromatography/tandem mass spectrometry based targeted proteomics quantification of P-glycoprotein in various biological samples
  publication-title: Rapid Commun Mass Spectrom
  doi: 10.1002/rcm.5026
– volume: 84
  start-page: 1
  year: 2012
  ident: 10.1124/dmd.113.053819_bib5
  article-title: Membrane protein quantification by peptide-based mass spectrometry approaches: studies on the organic anion-transporting polypeptide family
  publication-title: J Proteomics Bioinform
– volume: 89
  start-page: 210
  year: 2011
  ident: 10.1124/dmd.113.053819_bib10
  article-title: Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.2010.255
– volume: 66
  start-page: 818
  year: 2008
  ident: 10.1124/dmd.113.053819_bib17
  article-title: The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range
  publication-title: Br J Clin Pharmacol
  doi: 10.1111/j.1365-2125.2008.03287.x
– volume: 18
  start-page: 937
  year: 2008
  ident: 10.1124/dmd.113.053819_bib16
  article-title: Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0b013e32830d733e
– volume: 50
  start-page: 441
  year: 2012
  ident: 10.1124/dmd.113.053819_bib41
  article-title: SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians
  publication-title: Clin Chem Lab Med
  doi: 10.1515/cclm.2011.804
– volume: 17
  start-page: 861
  year: 2012
  ident: 10.1124/dmd.113.053819_bib37
  article-title: Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults
  publication-title: Antivir Ther
  doi: 10.3851/IMP2095
– volume: 55
  start-page: 4740
  year: 2012
  ident: 10.1124/dmd.113.053819_bib20
  article-title: Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions
  publication-title: J Med Chem
  doi: 10.1021/jm300212s
– volume: 44
  start-page: 62
  year: 2006
  ident: 10.1124/dmd.113.053819_bib26
  article-title: Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver
  publication-title: Hepatology
  doi: 10.1002/hep.21214
– volume: 40
  start-page: 1085
  year: 2012
  ident: 10.1124/dmd.113.053819_bib6
  article-title: In vitro evaluation of hepatic transporter-mediated clinical drug-drug interactions: hepatocyte model optimization and retrospective investigation
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.111.043489
– volume: 276
  start-page: 35669
  year: 2001
  ident: 10.1124/dmd.113.053819_bib42
  article-title: Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M103792200
– volume: 83
  start-page: 279
  year: 2012
  ident: 10.1124/dmd.113.053819_bib44
  article-title: Absolute immunoquantification of the expression of ABC transporters P-glycoprotein, breast cancer resistance protein and multidrug resistance-associated protein 2 in human liver and duodenum
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2011.10.017
– volume: 717
  start-page: 67
  year: 2012
  ident: 10.1124/dmd.113.053819_bib14
  article-title: Development of a multiplex UPLC-MRM MS method for quantification of human membrane transport proteins OATP1B1, OATP1B3 and OATP2B1 in in vitro systems and tissues
  publication-title: Anal Chim Acta
  doi: 10.1016/j.aca.2011.12.005
– volume: 40
  start-page: 295
  year: 2012
  ident: 10.1124/dmd.113.053819_bib23
  article-title: Pharmacokinetic/pharmacodynamic modeling in inflammation
  publication-title: Crit Rev Biomed Eng
  doi: 10.1615/CritRevBiomedEng.v40.i4.50
– volume: 3
  start-page: 276
  year: 2010
  ident: 10.1124/dmd.113.053819_bib4
  article-title: Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study
  publication-title: Circ Cardiovasc Genet
  doi: 10.1161/CIRCGENETICS.109.898502
– volume: 15
  start-page: 513
  year: 2005
  ident: 10.1124/dmd.113.053819_bib18
  article-title: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/01.fpc.0000170913.73780.5f
– volume: 52
  start-page: 235
  year: 2002
  ident: 10.1124/dmd.113.053819_bib24
  article-title: Rhabdomyolysis associated with cerivastatin plus gemfibrozil combined regimen
  publication-title: Br J Gen Pract
– volume: 14
  start-page: 429
  year: 2004
  ident: 10.1124/dmd.113.053819_bib28
  article-title: High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)
  publication-title: Pharmacogenetics
  doi: 10.1097/01.fpc.0000114750.08559.32
– volume: 87
  start-page: 558
  year: 2010
  ident: 10.1124/dmd.113.053819_bib43
  article-title: ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.2009.232
– volume: 30
  start-page: 1188
  year: 2013
  ident: 10.1124/dmd.113.053819_bib46
  article-title: Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide
  publication-title: Pharm Res
  doi: 10.1007/s11095-012-0956-5
– volume: 281
  start-page: 26501
  year: 2006
  ident: 10.1124/dmd.113.053819_bib35
  article-title: Exploiting reaction intermediates of the ATPase reaction to elucidate the mechanism of transport by P-glycoprotein (ABCB1)
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M601917200
– volume: 75
  start-page: 455
  year: 2004
  ident: 10.1124/dmd.113.053819_bib38
  article-title: The effect of gemfibrozil on the pharmacokinetics of rosuvastatin
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/j.clpt.2003.12.014
– volume: 311
  start-page: 228
  year: 2004
  ident: 10.1124/dmd.113.053819_bib39
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.104.068536
– volume: 72
  start-page: 685
  year: 2002
  ident: 10.1124/dmd.113.053819_bib3
  article-title: Gemfibrozil greatly increases plasma concentrations of cerivastatin
  publication-title: Clin Pharmacol Ther
  doi: 10.1067/mcp.2002.128469
– volume: 102
  start-page: 787
  year: 2013
  ident: 10.1124/dmd.113.053819_bib33
  article-title: Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype
  publication-title: J Pharm Sci
  doi: 10.1002/jps.23436
– volume: 12
  start-page: 5815
  year: 2011
  ident: 10.1124/dmd.113.053819_bib34
  article-title: Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms12095815
– volume: 201
  start-page: 731
  year: 2001
  ident: 10.1124/dmd.113.053819_bib7
  article-title: [Rhabdomyolysis associated with combined treatment of cerivastatin and gemfibrozil]
  publication-title: Rev Clin Esp
  doi: 10.1016/S0014-2565(01)70966-6
– volume: 40
  start-page: 852
  year: 2012
  ident: 10.1124/dmd.113.053819_bib9
  article-title: Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.111.043810
– volume: 9
  start-page: 237
  year: 2013
  ident: 10.1124/dmd.113.053819_bib8
  article-title: Species differences in drug transporters and implications for translating preclinical findings to humans
  publication-title: Expert Opin Drug Metab Toxicol
  doi: 10.1517/17425255.2013.741589
– volume: 109
  start-page: 261
  year: 2000
  ident: 10.1124/dmd.113.053819_bib2
  article-title: Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil
  publication-title: Am J Med
  doi: 10.1016/S0002-9343(00)00514-3
– volume: 20
  start-page: 112
  year: 2010
  ident: 10.1124/dmd.113.053819_bib12
  article-title: HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0b013e328335b02d
– volume: 75
  start-page: 415
  year: 2004
  ident: 10.1124/dmd.113.053819_bib27
  article-title: Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/j.clpt.2003.12.016
– volume: 25
  start-page: 1469
  year: 2008
  ident: 10.1124/dmd.113.053819_bib19
  article-title: Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria
  publication-title: Pharm Res
  doi: 10.1007/s11095-008-9532-4
– volume: 359
  start-page: 789
  year: 2008
  ident: 10.1124/dmd.113.053819_bib22
  article-title: SLCO1B1 variants and statin-induced myopathy—a genomewide study
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0801936
– volume: 5
  start-page: 1
  year: 2013
  ident: 10.1124/dmd.113.053819_bib29
  article-title: Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1
  publication-title: Genome Med
  doi: 10.1186/gm405
– volume: 34
  start-page: 2
  year: 2013
  ident: 10.1124/dmd.113.053819_bib13
  article-title: Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption
  publication-title: Biopharm Drug Dispos
  doi: 10.1002/bdd.1810
– volume: 27
  start-page: 425
  year: 2006
  ident: 10.1124/dmd.113.053819_bib40
  article-title: Transporters as a determinant of drug clearance and tissue distribution
  publication-title: Eur J Pharm Sci
  doi: 10.1016/j.ejps.2005.12.003
– volume: 54
  start-page: 1609
  year: 2009
  ident: 10.1124/dmd.113.053819_bib47
  article-title: The SLCO1B1*5 genetic variant is associated with statin-induced side effects
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2009.04.053
– volume: 29
  start-page: 2860
  year: 2012
  ident: 10.1124/dmd.113.053819_bib45
  article-title: Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions
  publication-title: Pharm Res
  doi: 10.1007/s11095-012-0792-7
– volume: 40
  start-page: 93
  year: 2012
  ident: 10.1124/dmd.113.053819_bib36
  article-title: Absolute quantification and differential expression of drug transporters, cytochrome P450 enzymes, and UDP-glucuronosyltransferases in cultured primary human hepatocytes
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.111.042275
– volume: 9
  start-page: 3535
  year: 2012
  ident: 10.1124/dmd.113.053819_bib21
  article-title: Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes
  publication-title: Mol Pharm
  doi: 10.1021/mp300379q
– volume: 9
  start-page: 215
  year: 2010
  ident: 10.1124/dmd.113.053819_bib11
  article-title: Membrane transporters in drug development
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd3028
– volume: 40
  start-page: 83
  year: 2012
  ident: 10.1124/dmd.113.053819_bib30
  article-title: Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.111.042259
– volume: 283
  start-page: 1552
  year: 1997
  ident: 10.1124/dmd.113.053819_bib31
  article-title: Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(24)37149-6
SSID ssj0014439
Score 2.494532
Snippet Interindividual variability in protein expression of organic anion-transporting polypeptides (OATPs) OATP1B1, OATP1B3, OATP2B1, and multidrug resistance-linked...
SourceID pubmedcentral
proquest
pubmed
crossref
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 78
SubjectTerms Adolescent
Adult
Aged
Aged, 80 and over
Alleles
ATP Binding Cassette Transporter, Subfamily B
ATP Binding Cassette Transporter, Subfamily B, Member 1 - genetics
Carbamates - metabolism
Child
Child, Preschool
Chromatography, Liquid - methods
Female
Fluorobenzenes - metabolism
Haplotypes - genetics
Hepatocytes - metabolism
Humans
Individuality
Infant
Liver - metabolism
Male
Middle Aged
Organic Anion Transporters - genetics
Piperidines - metabolism
Polymorphism, Single Nucleotide - genetics
Pyrimidines - metabolism
Rosuvastatin Calcium
Sulfonamides - metabolism
Tandem Mass Spectrometry - methods
Young Adult
Title Interindividual Variability in Hepatic Organic Anion-Transporting Polypeptides and P-Glycoprotein (ABCB1) Protein Expression: Quantification by Liquid Chromatography Tandem Mass Spectroscopy and Influence of Genotype, Age, and Sex
URI https://dx.doi.org/10.1124/dmd.113.053819
https://www.ncbi.nlm.nih.gov/pubmed/24122874
https://www.proquest.com/docview/1469214584
https://pubmed.ncbi.nlm.nih.gov/PMC3876790
Volume 42
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9NAEF615YUXxE24tEiogBKH2Lt2vLylITQCilKUor5ZPtatpdROkxgafjC_g9nDV9pK0BfL8pF1PPPtHJ6dD6HXYUyckPLY4CF3DUoD0wCrGBq-Q0O4hZsOl1W-35zxEf18bB9vbZ_XqpbyVdANf1-5ruQmUoVjIFexSvY_JFv-KByAfZAvbEHCsP0nGct0XlItqfoBga_quy1X8435XPZjVestw_YghScxynbmIkkwyWYQiMK0EXHVrHli7M_WYSbbNyRCMdzB3nDPFMmDiT42utDFs7Io5DD3Vb2R0iTwZr8m53kSibYFGbjDuiV2eyqy1WftA3DWJen9SrTRzOZrXZCsqVKE77rP00xkhuW0pZjfZX0pv6h70h8X-YngvwYlnhVEH1FSFqGVU_7CX2otPvVPfvlllc_op2aH--6vQWBRWYiUz5VDPUiXp1XV5DiTRH7DbJFyGK896raH3fagW8-amHQjazKtlu2kjfrYSdUwXL2AUZ1oYVqtiaunUnusZzDb1i29tSGxYMCepAkuLQ21LiFKmQ3FYlQ4IO7Vps2ioI_RWSRoeLowd7rK1tT0fH4mFR2cMkvQGFQmviy8nBwMCdi_Putto1sWRFaC9OPLYfXhjVKiIkb9l3SfUxj8fXNo0UVbj3OdS3c5ZNusPK65ctO76I6OwfBAAeoe2uLpfbSrZbLu4Pr77-BdXJfWA_RnA3W4hjqcpFijDmvU4cuow3XUYRA_bqIOv5WYe4c14nCFuA-4iTccrLHCG27iDSu8YYE3XMebHK_EG85iXOCtgwFtHXkesPYQHX0aTYdjQ7OlGCFEMSuYbGnAIocElst46LMIXrJDHCYKIWxmu2ZMuMtc34cgx3ZjRoJ-7LgO4w74sXZIyCO0k2Ypf4KwTwlM2pSQmHJKY-6GMTV7JOD9KHAYi1vIKATuhZpKQDDazDyZUrCoB7oCO8RTutJCb8rr56qJzrVXmoX-eDoEUK69BzC49p5XhaJ5YBvFB08_5Vm-FGkNJpgYXNpCj5XileMXyttC_YZKlheIvvvNM2lyKvvvawQ9vfGdz9Dtak56jnZWi5y_gNhmFbyUaPwLhsxd9A
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Interindividual+Variability+in+Hepatic+Organic+Anion-Transporting+Polypeptides+and+P-Glycoprotein+%28ABCB1%29+Protein+Expression%3A+Quantification+by+Liquid+Chromatography+Tandem+Mass+Spectroscopy+and+Influence+of+Genotype%2C+Age%2C+and+Sex&rft.jtitle=Drug+metabolism+and+disposition&rft.au=Prasad%2C+Bhagwat&rft.au=Evers%2C+Raymond&rft.au=Gupta%2C+Anshul&rft.au=Hop%2C+Cornelis+E.+C.+A.&rft.date=2014-01-01&rft.pub=The+American+Society+for+Pharmacology+and+Experimental+Therapeutics&rft.issn=0090-9556&rft.eissn=1521-009X&rft.volume=42&rft.issue=1&rft.spage=78&rft.epage=88&rft_id=info:doi/10.1124%2Fdmd.113.053819&rft_id=info%3Apmid%2F24122874&rft.externalDocID=PMC3876790
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-9556&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-9556&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-9556&client=summon